7 Min Read
ZURICH (Reuters) - U.S. regulators have recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine, as they investigate rare blood clotting in six women.
Syringes are prepared to administer the AstraZeneca coronavirus disease (COVID-19) vaccine at a new mass vaccination centre in WiZink sports arena in Madrid, Spain, April 9, 2021. REUTERS/Sergio Perez
J&J also said it was stopping the rollout of its vaccine in Europe.
The move comes after Europe’s drug regulator earlier this month said it had found a possible link between AstraZeneca’s COVID-19 vaccine and very rare blood clots in some adults who had received the shot.
Italy recommended on Wednesday that AstraZeneca's COVID-19 shot only be used on those over 60 and Britain that people under 30 should get an alternative, due to possible links between the vaccine and very rare cases of blood clots.
What We Know On Blood Clots Linked To AstraZeneca, J&J Vaccines What We Know On Blood Clots Linked To AstraZeneca, J&J Vaccines With both the AstraZeneca and J&J vaccines, the reports involve extremely rare clotting, including a type of blood clot called cerebral venous sinus thrombosis that were seen in combination with low levels of blood platelets.
Most adverse cases occurred within two weeks of receiving the first vaccine jab (Representational)
Zurich:
US regulators have recommended pausing the use of Johnson & Johnson s COVID-19 vaccine, as they investigate rare blood clotting in six women.
J&J also said it was stopping the rollout of its vaccine in Europe.
UPDATE 1-EXPLAINER-How worried should we be about blood clots linked to AstraZeneca and J&J vaccines? Reuters 3 hrs ago By John Miller and Ludwig Burger
(Adds company code for Johnson & Johnson, details including that pause only expected to last a few days)
By John Miller and Ludwig Burger
ZURICH, April 13 (Reuters) - U.S. regulators have recommended pausing the use of Johnson & Johnson s COVID-19 vaccine as they investigate rare blood clotting in six women, including one who died.
J&J also said it was delaying the rollout of its vaccine in Europe. U.S. officials said the temporary halt is expected only to last a few days.
7 Min Read
ZURICH (Reuters) - U.S. regulators have recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine as they investigate rare blood clotting in six women, including one who died.
Syringes are prepared to administer the AstraZeneca coronavirus disease (COVID-19) vaccine at a new mass vaccination centre in WiZink sports arena in Madrid, Spain, April 9, 2021. REUTERS/Sergio Perez
J&J also said it was delaying the rollout of its vaccine in Europe. U.S. officials said the temporary halt is expected only to last a few days.
The move comes after Europe’s drug regulator said it had found a possible link between AstraZeneca’s COVID-19 vaccine and very rare blood clots in some adults who had received the shot.